Antioxidant Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Antioxidant Therapy | |
|---|---|
| Category | Neuroprotective / Disease-Modifying |
| Target Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease, Stroke |
| Mechanism | Scavenge ROS/RNS, enhance endogenous antioxidants, protect mitochondria |
| Approaches | Direct antioxidants, mitochondrial antioxidants, Nrf2 activators, metal chelators |
Oxidative stress is a hallmark of neurodegeneration, characterized by excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) that overwhelm cellular antioxidant defenses. Antioxidant therapies aim to neutralize these harmful species, protect neuronal function, and potentially slow disease progression. While preclinical studies have shown remarkable promise, clinical translation has been challenging[1].
Lipid-soluble antioxidant protecting neuronal membranes.
Water-soluble extracellular antioxidant.
Mitochondrial electron transport chain antioxidant.
CoQ10 conjugated to triphenylphosphonium for mitochondrial targeting.
Free radical scavenger approved for ALS.
Glutathione precursor and direct antioxidant.
Glutathione peroxidase mimetic.
The Nrf2 transcription factor regulates expression of antioxidant and cytoprotective genes.
Isothiocyanate from broccoli sprouts.
Synthetic triterpenoid Nrf2 activator.
Approved for MS, Nrf2 activator.
Metal dysregulation contributes to oxidative stress through Fenton chemistry.
Iron chelator, tested in AD.
Metal-protein attenuating compounds.
Oral iron chelator.
Synthetic SOD/catalase mimetics.
| Compound | Indication | Phase | Outcome |
|---|---|---|---|
| CoQ10 | PD | II | Modest benefit |
| CoQ10 | ALS | III | Failed |
| Edaravone | ALS | III | Approved |
| Vitamin E | AD | III | Mixed |
| Sulforaphane | AD | II | Ongoing |
| PBT2 | AD | II | Biomarker effect |
| MitoQ | PD | II | Ongoing |
The study of Antioxidant Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3(3):205-214. ↩︎
Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997;336(17):1216-1222. ↩︎
Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550. ↩︎
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 2017;16(7):505-512. ↩︎ ↩︎
Zhang Y, Talwar P, Tschanz J, et al. Sulforaphane for the treatment of Alzheimer's disease: a systematic review. Advances in Experimental Medicine and Biology. 2020;1260:185-195. ↩︎
Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337(8753):1304-1308. ↩︎
Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurology. 2008;7(9):779-786. ↩︎